SynthesisJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2023
A systematic review and meta-analysis comparing radiofrequency catheter ablation with medical therapy for ventricular tachycardia in patients with ischemic and non-ischemic cardiomyopathies.
Synthesis in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Treatment of ventricular tachycardia with catheter ablation versus anti-arrhythmic drug titration: a systematic review and meta-analysis of randomized controlled trials.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2023Pooled it
- Dose escalation for stereotactic arrhythmia radioablation of recurrent ventricular tachyarrhythmia - a phase II clinical trial.Radiation oncology (London, England) · 2023Trial
- Review
- Extended reality simulator for dynamic visualization and evaluation of stereotactic arrhythmia radioablation (STAR) treatment plans within RAVENTA trial.European heart journal. Digital health · 2026Article
- Outcomes of catheter ablation for ventr tachycardia in structural heart disease: a meta-analysis and quality appraisal of trials.European heart journal open · 2026Review
- Ventricular Duration Map Area as a Valuable and Effective Target for VT Ablation End Point in Ischemic Cardiomyopathy: The VEDUM FREEDOM Study.Circulation. Arrhythmia and electrophysiology · 2025Article
- Neuromodulation for ventricular arrhythmias: progress-but are we there yet?Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2025Article
- Prognostic value of non-invasive programmed ventricular stimulation after VT ablation to predict VT recurrences.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2025Article
- Outcomes in Catheter Ablation of Sustained Ventricular Tachycardia in Myocarditis Compared with Ischemic Heart Disease.Reviews in cardiovascular medicine · 2025Article
- Contemporary Trends in Pulsed Field Ablation for Cardiac Arrhythmias.Journal of cardiovascular development and disease · 2024Review
- Mapping and ablation of ventricular tachycardia using dual-energy lattice-tip focal catheter: early feasibility and safety study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024Article
- Management of Ventricular Arrhythmias in Heart Failure: Can Less Be More?Current cardiology reports · 2024Review
- Early Diagnosis of Problems Related to the Self-Organization of the Cardiovascular System Based on the Interplay between RR and JT Cardiac Intervals.Diagnostics (Basel, Switzerland) · 2024Article
- Efficacy and safety of focal pulsed-field ablation for ventricular arrhythmias: two-centre experience.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024Observational
- Catheter Ablation for Ventricular Tachycardia After MI: A Reconstructed Individual Patient Data Meta-analysis of Randomised Controlled Trials.Arrhythmia & electrophysiology review · 2023Article
- Solving the Reach Problem: A Review of Present and Future Approaches for Addressing Ventricular Arrhythmias Arising from Deep Substrate.Arrhythmia & electrophysiology review · 2023Review
- Anti-racist strategies for clinical and translational research: Design, implementation, and lessons learned from a new course.Journal of clinical and translational science · 2023Article
- Management of Complex Arrythmias: Optimal Timing of Catheter Ablation for Ventricular Tachycardia.Journal of clinical medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with cardiomyopathy, radiofrequency catheter ablation (CA) for ventricular tachycardia (VT) is an adjunctive and alternative treatment option to long-term anti-arrhythmic drug therapy. We sought to compare CA with medical therapy for the management of VT in patients with ischemic and non-ischemic cardiomyopathies.
methodsMEDLINE, Cochrane, and ClinicalTrials.gov databases were evaluated for relevant studies.
resultsEleven studies with 2126 adult patients were included (711 in CA, 1415 in medical therapy). In the randomized controlled trial (RCT) analysis, CA reduced risk of recurrent VT (risk ratio (RR) 0.79 [95% CI 0.67 to 0.93], p = 0.005), ICD shocks (RR 0.64 [95% CI 0.45 to 0.89] p = 0.008), and cardiac hospitalizations (RR 0.76 [95% CI 0.63 to 0.92] p = 0.005). There was no difference in all-cause mortality (RR 0.94, p = 0.71). In combined RCT and observational study analysis, there was a trend for reduction in all-cause mortality (RR 0.75 [95% CI 0.55 to 1.02] p = 0.07). In subgroup analysis of studies with mean left ventricular ejection fraction (LVEF) < 35%, CA demonstrated reduction in mortality (RR 0.71, p = 0.004), ICD shocks (RR 0.63, p = 0.03), VT recurrence (RR 0.76, p = 0.004), and cardiac hospitalizations (RR 0.75, p = 0.02). The subgroup of early CA prior to ICD shocks demonstrated reduction in ICD shocks (RR 0.57, p < 0.001) and VT recurrence (RR 0.74, p = 0.01).
conclusionsCA for VT demonstrated a lower risk of VT recurrence, ICD shocks, and hospitalization in comparison to medical therapy. The subgroups of early CA and LVEF < 35% demonstrated better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.